Femara 5

ACTIVE HALF-LIFE 2 days
CLASSIFICATION Non-steroidal aromatase inhibitor
DOSAGE 2.5 - 5 mg/day
ACNE No
WATER RETENTION No
HBR No
HEPATOTOXICITY No
AROMATIZATION No
MANUFACTURER Nakon Medical
WAREHOUSE International Warehouse 3
SUBSTANCE Letrozole ,

Femara, produced by Nakon Medical, is an anti-estrogen medication that is widely used in both medical and athletic settings. In medicine, it is primarily prescribed for treating estrogen-dependent cancers, such as breast cancer in women. In the realm of sports, it helps mitigate the negative effects associated with estrogen-steroid usage, including water retention and gynecomastia in men, among other issues.

This non-steroidal aromatase inhibitor contains Letrozole as its active ingredient. It is approved for human use, is non-steroidal, lacks androgenic properties, is not overly toxic, does not harm the liver, and does not contain narcotic or addictive substances.

When administered, Femara acts as an aromatase inhibitor, impacting the enzyme responsible for estrogen production. It works by inhibiting the cytochrome P450 enzyme within aromatase, leading to a significant decrease in estrogen activity—by 75-95% from baseline levels when used over time.

Femara is categorized as a third-generation aromatase inhibitor. Its counterpart Anastrozole is similar but not identical, while Clomid and Nolvadex function as estrogen receptor blockers. These alternatives differ in their mechanisms of action and ultimate effects, as they solely bind to estrogen receptors rather than influencing estrogen production directly.

Importantly, Femara is generally considered safe for human use when taken as directed, without causing notable side effects. However, misuse or predisposition to certain conditions may increase the risk of complications affecting various systems—including digestive (nausea, dry mouth), central nervous system (dizziness, depression), respiratory (shortness of breath, cough), and musculoskeletal (joint pain, osteoporosis). In case of an overdose, symptomatic treatment is advised.

Femara is taken orally and can be consumed regardless of food. Upon ingestion, it is quickly and completely absorbed by the gastrointestinal tract, with a bioavailability of 99%, unaffected by food intake.

The recommended dosage ranges from 0.25 to 5 mg daily, tailored to individual needs and tolerance levels. The drug can be used according to one of two strategies: 1) by starting with preventive use to avoid complications from estrogenic steroids, or 2) by being integrated into steroid cycles to address estrogen-related complications after symptoms arise. In either case, Femara effectively helps prevent estrogen-related side effects, such as water retention, increased body fat, and gynecomastia in men.

Before beginning Femara, it’s crucial to assess potential risks. Consultation with a specialist is advised to identify and rule out contraindications, which include pregnancy, breastfeeding, and certain endocrine issues for women, as well as known substance intolerance in both genders and in children.

Caution is also recommended for individuals with conditions like glucose-galactose malabsorption, lactase deficiency, and lactase intolerance that might lead to adverse effects. Generally, dosage adjustments are not needed.

Keep out of reach of children. Intended for adults only.